Stock Analiz

Burning Rock Biotech Ltd BNR

Medical Specialities · IPO 2020 · data as of November 13, 2026

$13.29Market cap $140M
Open the interactive analysis →

Burning Rock Biotech Ltd (BNR) is a healthcare company listed in the US with a market value of about $140M. In fiscal year 2025 it had revenue of $77M and net income of -$8M, a net margin of -10.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 3% a year, a 5-year average ROIC of -43%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.

About Burning Rock Biotech

Burning Rock Biotech is listed in the US and classified in medical specialities, IPO year 2020. Revenue went from $66M in 2020 to $77M in 2025, growth of about 3.2% a year. It was profitable in 0 of the last 6 years in our data. It spends 31% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.8
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-3.4%
Shareholder yield0.0%
Intrinsic value vs. price−81%

Growth and quality

Revenue growth (1 yr)9.2%
Revenue growth (5 yrs, per year)3.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-105.7%
ROIC (5-yr avg.)-43.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$77M$71M$76M$82M$80M$66M
Net income-$8M-$47M-$92M-$141M-$125M-$62M
Free cash flow-$5M-$13M-$37M-$75M-$107M-$21M
EPS (diluted)$-0.75$-4.50$-8.73$-13.35$-11.85$-5.92
Net margin-10.3%-67.2%-121.6%-172.4%-156.9%-94.7%
ROIC-7.5%-44.6%-67.7%-64.1%-32.6%-17.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Burning Rock Biotech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Burning Rock Biotech pay a dividend?

Not currently.

Is Burning Rock Biotech a good stock to buy?

We do not give buy or sell advice. Burning Rock Biotech scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.